Energy Drinks, AI-Guided Hearts, and New Cancer Drugs Headline AHA 2026

Five stories from the past 72 hours: an urgent public-health signal from Chicago, two AI cardiology readouts, a new oncology approval, and emerging evidence on how psilocybin rewires the brain.

Saturday, 7 November: Energy Drinks Linked to Cardiac Arrest and Heart Attack in Under-35s

A preliminary analysis presented at the American Heart Association's Scientific Sessions 2026 in Chicago has drawn fresh attention to the cardiovascular risks of caffeinated energy drinks and stimulant supplements among young adults. Researchers reviewed more than 28,000 FDA adverse-event reports filed between 2017 and 2025. Products containing caffeine or other stimulants were approximately eleven times more likely to be associated with cardiac arrest, and four and a half times more likely to be associated with a heart attack, compared with reports for stimulant-free products. Nearly 45 percent of the cardiovascular events tied to these products involved people between the ages of 18 and 34.

The study's authors are careful to note the limits of voluntary adverse-event reporting: the data cannot establish causation, and the absolute event rate among all energy-drink consumers is unknown. Possible confounders include mixing drinks with alcohol, consuming them before intense exercise, or using other stimulant substances. Still, the pattern across tens of thousands of reports is consistent, and Medical News Today notes that the FDA has flagged these products for additional scrutiny in prior safety communications.

For parents, school nurses, and primary-care clinicians — particularly in Cyprus, Greece, and neighbouring Mediterranean countries where high-caffeine drinks are increasingly marketed to teenagers and young athletes — this analysis offers a practical prompt for a conversation. Stage of evidence: observational analysis of regulatory data; presented as a conference abstract, not yet peer-reviewed.

Saturday, 7 November: AI Plaque Analysis Halves Heart Attack Rate in Prospective Registry

HeartFlow, a digital-health company that layers machine-learning analysis onto coronary CT angiography (CCTA) images, presented prospective real-world outcomes from its DECIDE registry at AHA 2026. Among more than 6,000 clinically stable patients who underwent CCTA with plaque detected, those whose cardiologists had access to HeartFlow's AI plaque-analysis tool showed a 34 percent reduction in major adverse cardiovascular events and approximately half the rate of non-fatal heart attacks at one year, compared with CCTA imaging alone.

The tool quantifies plaque type (calcified versus non-calcified), volume, and anatomical location, giving clinicians a richer picture than visual CT reading alone — and helping distinguish patients who need aggressive statin therapy or intervention from those who can be safely managed with lifestyle changes. Earlier data from SCCT 2025, reported by Cardiovascular Business, showed that medical management changed in more than half of patients after plaque analysis was added to the clinical picture.

Independent cardiologists note that the DECIDE data are company-sponsored and have not yet appeared in a peer-reviewed journal; a full publication in JACC Cardiovascular Imaging is expected in early 2027. The American College of Cardiology and AHA published scientific statements in late 2025 supporting quantitative plaque analysis for risk stratification. Stage of evidence: prospective registry, company-sponsored, conference presentation; peer-reviewed publication pending.

Thursday, 5 November: FDA Approves Amivantamab for EGFR-Amplified Head and Neck Cancer

The United States Food and Drug Administration granted accelerated approval on 5 November to amivantamab (Rybrevant) combined with hyaluronidase-lpuj for adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumours carry EGFR amplification and who have progressed on or after platinum-based chemotherapy. This follows a busy month for the FDA: Endocrinology Advisor's calendar and The Pharma Letter also note multiple other PDUFA dates through November 30.

Amivantamab is a bispecific antibody — a molecule engineered to grab two separate receptor targets simultaneously — blocking both EGFR and MET, two proteins that drive tumour growth when overactivated. EGFR is amplified in a meaningful subset of HNSCC patients who have few effective options after platinum failure. The accelerated approval is based on objective response-rate data from an early-phase study; a phase-3 confirmatory trial is required by the FDA as a condition of the approval pathway. If that trial confirms clinical benefit, the approval would be converted to full status.

Head and neck squamous cell carcinoma accounts for roughly 890,000 new diagnoses worldwide each year. It is associated with smoking, alcohol consumption, and HPV infection, and is diagnosed disproportionately in lower-income settings where late-stage presentation is common. Stage of evidence: accelerated approval based on objective response rate; overall survival data pending confirmatory phase-3 trial.

Friday, 6 November: Coronary Calcium Scores Match Conventional Risk Tools — With Fewer Statin Prescriptions

A large observational study of nearly 5,800 asymptomatic adults, reported by ScienceDaily and covered by Medical Xpress this week, found that coronary artery calcium (CAC) scoring predicted major cardiovascular events at a rate comparable to the widely used pooled cohort equations. The key difference: CAC scoring recommended statin therapy to substantially fewer people, without meaningfully increasing event rates among those it classified as low-risk.

The coronary calcium scan is a brief, low-dose, non-contrast CT of the chest that detects and quantifies calcified plaque deposited in the coronary arteries. A score of zero is associated with very low ten-year cardiovascular risk; progressively higher scores guide more intensive lipid-lowering. The finding reinforces ACC and ESC guidance positioning CAC as a "tie-breaker" for borderline-risk patients who might otherwise be started on statins based on age and risk-factor calculations alone.

For clinicians in Cyprus and across the broader eastern Mediterranean, where primary-prevention statin prescribing is inconsistent and coronary CT infrastructure has expanded significantly in recent years, the evidence offers a practical tool: a single scan can provide both risk stratification and a motivating "visual" for patients ambivalent about committing to lifelong medication. Stage of evidence: observational study; not a randomised trial, though consistent with the existing evidence base.

Wednesday, 22 October — Follow-up: Psilocybin Rewires the Brain More Selectively Than Thought

A study published in Nature Neuroscience on 22 October by researchers at UC Santa Cruz, and reported by News-Medical with supporting commentary from Nature Asia, has clarified how psilocybin — the active compound in certain mushrooms, currently under therapeutic review in several countries — reshapes cortical connectivity. Rather than uniformly increasing neural connections, the drug acts through two distinct cellular mechanisms: it boosts the formation of new dendritic spines (the small protrusions through which neurons receive signals) in prefrontal regions associated with flexible thinking and emotional regulation, while simultaneously suppressing activity in the default-mode network, the resting-state circuit implicated in rumination and rigid thought patterns.

Critically, the team found that the magnitude and persistence of new synapse formation depended heavily on prior chronic stress. In mice with a history of stress, psilocybin-induced connections persisted for several weeks; in non-stressed animals, the connections regressed within days. This suggests the drug's therapeutic mechanism may be potentiated by pre-existing pathological states — a finding with direct relevance to how phase-3 depression trials should be designed, particularly regarding baseline symptom-severity thresholds for enrolment.

Therapeutic psilocybin remains illegal in all EU member states, including Cyprus and Greece, under current scheduling. Australia, the United Kingdom, and certain US states have approved limited clinical or supervised use. The European Medicines Agency is expected to issue a formal position on the therapeutic dossiers by mid-2027. This story is included as a follow-up on a rapidly developing evidence base; the primary citation is from October 22, seventeen days before this roundup. Stage of evidence: preclinical (mouse model) and human observational neuroimaging; not yet tested in a controlled therapeutic trial with patient outcomes.

---

This article is produced for journalistic and informational purposes only and does not constitute medical advice. Readers should consult a qualified clinician or pharmacist before making any change to their medication, diet, or health regimen.